Fundz

Waypoint Bio raises $14.5M in seed funding led by Hummingbird Ventures for in vivo spatial pooled screening technology

PRIVATEJun 28, 2024

Amount Raised

$14.5 Million

Round Type

Seed

New YorkBiotechnologyHealth CareTherapeutics

Investors

Fifty YearsRecode VenturesHummingbird Ventures

Description

Waypoint Bio, a biotechnology company focusing on cell therapies for solid tumors, has secured $14.5 million in seed funding led by Hummingbird Ventures. The company's platform combines spatial biology with pooled screening to enable the engineering of cell therapy designs for historically intractable diseases, such as pancreatic cancer.

Who to call at Waypoint Bio, and when

A new round usually means Waypoint Bio is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Waypoint Bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Waypoint Bio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Waypoint Bio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Waypoint Bio

Location

New York, New York, United States

About

Waypoint Bio is a biotechnology company pioneering novel cell therapies for solid tumors using in vivo spatial pooled screening technology. The company's platform uniquely combines spatial biology with pooled screening for the purpose of drug discovery, enabling the simultaneous measurement of cell therapy candidates' navigation in the solid tumor microenvironment. Waypoint will use its seed financing toward designing CAR T-cell therapies with superior efficacy against the tumor microenvironment, and later, Treg therapies for autoimmune diseases.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Waypoint Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsDavid P., Co-founder and CSO hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Waypoint Bio's next move

See what Strategic adds

Waypoint Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.